LIGAND PHARMACEUTICALS (LGND) Stock Overview
NASDAQ:LGND - US53220K5048 - Common Stock
LGND Key Statistics, Chart & Performance
The current stock price of LGND is 161.71 USD. In the past month the price increased by 21.84%. In the past year, price increased by 52.85%.
LGND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
| JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.44 | 250.88B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.17 | 120.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
| GSK | GSK PLC-SPON ADR | 8.76 | 79.97B | ||
| ZTS | ZOETIS INC | 25.14 | 69.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.97 | 47.34B |
Related stock screener links
About LGND
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Company Info
LIGAND PHARMACEUTICALS
3911 Sorrento Valley Blvd, Suite 110
San Diego CALIFORNIA 92121 US
CEO: John L. Higgins
Employees: 68
Phone: 18585507500
LIGAND PHARMACEUTICALS / LGND FAQ
What is the stock price of LIGAND PHARMACEUTICALS today?
The current stock price of LGND is 161.71 USD. The price increased by 1.09% in the last trading session.
What is the ticker symbol for LIGAND PHARMACEUTICALS stock?
The exchange symbol of LIGAND PHARMACEUTICALS is LGND and it is listed on the Nasdaq exchange.
On which exchange is LGND stock listed?
LGND stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIGAND PHARMACEUTICALS stock?
13 analysts have analysed LGND and the average price target is 170.6 USD. This implies a price increase of 5.49% is expected in the next year compared to the current price of 161.71. Check the LIGAND PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIGAND PHARMACEUTICALS worth?
LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 3.17B USD. This makes LGND a Mid Cap stock.
How many employees does LIGAND PHARMACEUTICALS have?
LIGAND PHARMACEUTICALS (LGND) currently has 68 employees.
What are the support and resistance levels for LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a support level at 152.41. Check the full technical report for a detailed analysis of LGND support and resistance levels.
Is LIGAND PHARMACEUTICALS (LGND) expected to grow?
The Revenue of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 29.78% in the next year. Check the estimates tab for more information on the LGND EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LIGAND PHARMACEUTICALS (LGND) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LGND, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LGND, evaluating the profitability, health, valuation and growth aspects
- LIGAND PHARMACEUTICALS (LGND) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIGAND PHARMACEUTICALS (LGND) Sales and EPS estimates to see what analysts future expectations are.
- LIGAND PHARMACEUTICALS (LGND) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIGAND PHARMACEUTICALS (LGND) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIGAND PHARMACEUTICALS (LGND) Stock Chart to make your own analysis
- LIGAND PHARMACEUTICALS (LGND) Latest news and press-releases to stay up to date.
Does LIGAND PHARMACEUTICALS (LGND) stock pay dividends?
LGND does not pay a dividend.
When does LIGAND PHARMACEUTICALS (LGND) report earnings?
LIGAND PHARMACEUTICALS (LGND) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of LIGAND PHARMACEUTICALS (LGND)?
The PE ratio for LIGAND PHARMACEUTICALS (LGND) is 26.77. This is based on the reported non-GAAP earnings per share of 6.04 and the current share price of 161.71 USD. Check the full fundamental report for a full analysis of the valuation metrics for LGND.
What is the Short Interest ratio of LIGAND PHARMACEUTICALS (LGND) stock?
The outstanding short interest for LIGAND PHARMACEUTICALS (LGND) is 4.86% of its float. Check the ownership tab for more information on the LGND short interest.
LGND Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LGND. When comparing the yearly performance of all stocks, LGND is one of the better performing stocks in the market, outperforming 92.9% of all stocks.
LGND Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to LGND. LGND has an excellent financial health rating, but there are some minor concerns on its profitability.
LGND Financial Highlights
Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 6.04. The EPS increased by 20.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8% | ||
| ROE | -9.16% | ||
| Debt/Equity | 0 |
LGND Forecast & Estimates
13 analysts have analysed LGND and the average price target is 170.6 USD. This implies a price increase of 5.49% is expected in the next year compared to the current price of 161.71.
For the next year, analysts expect an EPS growth of 22.58% and a revenue growth 29.78% for LGND